Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894723 | 0.93 | PRKCA (0.48) | KCNH2NR1I2CYP3A4SCN5APRKCA | |
| SCHEMBL3092990 | 0.91 | PRKCA (0.41) | KCNH2NR1I2CYP3A4SCN5APRKCA | |
| SCHEMBL3080352 | 0.90 | PRKCA (0.48) | KCNH2NR1I2CYP3A4SCN5APRKCA | |
| SCHEMBL3083577 | 0.87 | KCNH2 (0.45) | KCNH2NR1I2CYP3A4SCN5APRKCA | |
| SCHEMBL3089899 | 0.85 | PRKCA (0.41) | KCNH2NR1I2CYP3A4SCN5APRKCA | |
| SCHEMBL3095670 | 0.85 | PRKCA (0.42) | KCNH2NR1I2CYP3A4SCN5APRKCA | |
| SCHEMBL3074886 | 0.83 | PRKCA (0.46) | KCNH2NR1I2CYP3A4SCN5APRKCA | |
| SCHEMBL3095015 | 0.83 | PRKCA (0.40) | KCNH2NR1I2CYP3A4SCN5APRKCA | |
| SCHEMBL4144670 | 0.83 | PRKCA (0.38) | KCNH2NR1I2CYP3A4SCN5APRKCA | |
| SCHEMBL4144672 | 0.83 | PRKCA (0.38) | KCNH2NR1I2CYP3A4SCN5APRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795247-B2 | Tetracyclic indole derivatives as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-09-14 | — | — | US | disclosed |
| US-20060100262-A1 | Tetracyclic indole derivatives as antiviral agents | ISTITUTO DI RICHERCHEDI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IRMB) (IT) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100262-A1 | Tetracyclic indole derivatives as antiviral agents | IDO1, ZC3HAV1, IDO2 | KCNH2 1341/4885NR1I2 144/4885CYP3A4 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.